AVADEL PHARMACEUTICALS PLC (NASDAQ:AVDL) Files An 8-K Other Events
On November 25, 2019, Avadel Pharmaceuticals plc issued a press release, a copy of which is furnished as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.
|99.1||Press release dated November 25, 2019, issued by Avadel Pharmaceuticals plc|
AVADEL PHARMACEUTICALS PLC Exhibit
EX-99.1 2 tm19237671_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Avadel Pharmaceuticals Achieves Enrollment Target in REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy – – – 205 patients enrolled; additional patients currently in screening will be allowed to enroll if eligible – – – Topline data from the REST-ON study expected in Q2 2020 DUBLIN,…
To view the full exhibit click